Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?

Emmert Roberts, Keith Humphreys

Research output: Contribution to journalComment/debatepeer-review

2 Downloads (Pure)


After years of minimal innovation in pharmacotherapeutics, impressive outcomes in the treatment of opioid use disorder are being obtained from a new way of delivering an old medication; long-acting injectable formulations of buprenorphine appear to produce compelling reductions in relapse to illicit opioid use not only during use but also following depot discontinuation. This commentary discusses potential mechanisms behind this observation, asks if the removal of the need for daily oral opioid agonist dosing furthers our understanding of addiction treatment and whether we should therefore consider expanding access to depot formulations.

Original languageEnglish
JournalDrug and Alcohol Review
Publication statusPublished - 31 Jul 2023

Cite this